Infilea

Clobetasol Propionate, the active ingredient in Infilea, is a topical corticosteroid presented as a skin‑applied formulation for local use. It is employed to reduce inflammation and relieve itching in various dermatologic conditions, particularly in adult patients with moderate to severe disease.

GNH USA supplies Infilea as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide.

Clobetasol Propionate is a high‑potency glucocorticoid used to manage inflammatory skin disorders.

- Psoriasis: diminishes plaque thickness and scaling. - Eczema (atopic dermatitis): alleviates redness, swelling and pruritus. - Dermatitis: reduces inflammatory lesions and associated discomfort. - Lichen planus: suppresses immune‑mediated skin lesions and itching.

Topical clobetasol may cause local and systemic reactions, most of which are dose‑ and duration‑dependent.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Dryness or peeling of the treated skin. - Mild erythema or folliculitis. - Temporary worsening of eczema (steroid‑induced flare).

Serious or Rare Side Effects: - Skin atrophy, striae, or telangiectasia with prolonged use. - Secondary infection (bacterial, fungal, or viral) of the treated area. - Systemic adrenal suppression, especially when applied over large surface areas or under occlusion.

When prescribing or dispensing Infilea, consider the following safety measures.

- Duration of Use: limit application to the shortest period necessary to achieve therapeutic effect. - Surface Area: avoid extensive or continuous use on large body areas. - Occlusion: do not cover treated skin with airtight dressings unless directed by a clinician. - Pre‑existing Infections: assess and treat any bacterial, fungal, or viral skin infection before initiating therapy. - Pediatric Use: use with caution in children; monitor for growth‑related side effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Clobetasol Propionate can interact with other agents that affect skin integrity or systemic corticosteroid levels.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use may increase risk of adrenal suppression. - Potent immunosuppressants (e.g., tacrolimus): may enhance local immunosuppression and infection risk.

Moderate Interactions (Monitor Closely): - Antifungal or antiviral topicals: may reduce efficacy of clobetasol if applied to the same site. - Skin‑sensitizing agents (e.g., benzoyl peroxide): could increase irritation. - Occlusive dressings: may increase systemic absorption, requiring monitoring.